Latest findings from the open-label extension (OLE) Phase 3 clinical trials Scarlet RoAD (NCT01224106) and Marguerite RoAD (NCT02051608) on gantenerumab (RG1450, RO4909832) continue to show significant reductions in the accumulation of amyloid plaques in patients with Alzheimer’s disease with and without amyloid-related imaging abnormalities-edema (ARIA-E).
Two prescription treatments for heart disease and angina — cilostazol and isosorbide mononitrate — show a potential to prevent or reduce vascular dementia, a study reports. They also can be safely used in people with a history of stroke, which was the focus of this research. Because vascular dementia and…
United Neuroscience’s vaccine candidate UB-311 was safe and well-tolerated in patients with mild Alzheimer’s disease, according to results from a Phase 2a clinical trial. Patients who participated in this trial are now eligible to enroll in a long-term follow-up study that will continue to assess the vaccine’s safety…
Preliminary data from a Phase 2 study suggests that treating early Alzheimer’s disease patients who are positive for herpes simplex virus with an antiviral medicine may help halt their cognitive decline. Hugo Lövheim, MD, PhD, at UmeÃ¥ University, Sweden, presented the results in a presentation titled “Valz Pilot…
AVP-786, an investigational oral therapy, significantly relieved agitated behaviors among patients with Alzheimer’s dementia, according to preliminary data from a Phase 3 trial by Avanir Pharmaceuticals. The treatment candidate was designed as a second-generation version of Nuedexta, a two-drug combo approved for pseudobulbar affect. AVP-786…
Alzinova‘s ALZ-101 vaccine — designed to target toxic forms of the amyloid beta protein that drive neurodegeneration in Alzheimer’s disease — was well-tolerated in non-human primates and displayed efficacy in a fish model of the disease. A clinical study in patients with early Alzheimer’s disease now is expected to start later…
The first patient has been dosed in Alkahest‘s Phase 2 clinical trial testing its investigational therapy, GRF6019, in individuals with severe Alzheimer’s disease. The study (NCT03765762) was designed to assess the safety and tolerability of the experimental treatment, as well as its impact on patients’ mental state and…
Two Phase 3 clinical trials testing the investigational therapy aducanumab in patients with early Alzheimer’s disease have been discontinued. Biogen and Eisai came to this decision after an analysis from an independent data monitoring committee indicated that the global ENGAGE (NCT02477800) and EMERGE (NCT02484547)…
Combining two dietary compounds found in green tea and carrots reversed cognitive deficits, lowered the accumulation of toxic amyloid beta, and reduced brain inflammation and oxidative damage in a mouse model of Alzheimer’s disease, a study reports. The study, “Combined treatment with the phenolics (−)-epigallocatechin-3-gallate and ferulic…
Neurotrope Bioscience announced that dosing of patients has started in its Phase 2 clinical trial to further evaluate Bryostatin-1, the company’s investigational candidate for the treatment of moderate to severe Alzheimer’s disease. “Completion of enrollment in our confirmatory Phase 2 trial is an important step toward understanding the transformative…
Get regular updates to your inbox.